Concordance between CSF $A\beta_{1-42}$ (<550 pg/mL) and [$^{18}$F]flutemetamol was 57% and 53%, using visual and quantitative approaches, respectively. Among discordant cases, most showed isolated [$^{18}$F] flutemetamol positivity (75% using visual, 77% using quantification). **Conclusions:** While further analyses are ongoing for the remaining 74 patients, preliminary findings highlight the added value of [$^{18}$F]flutemetamol over standard diagnostic work-up. Discordance between CSF $A\beta_{1-42}$ and [$^{18}$F]flutemetamol PET highlights the issue of biomarker interchangeability in clinical settings.

## IC-P-017 VOXEL-WISE DETERMINATION OF SENSITIVITY, SPECIFICITY, AND THRESHOLDS FOR AMYLOID POSITIVITY USING [$^{18}$F]FLORBETAPIR PET

**Tharick A. Pascoal**[1,2,3,4,5], Sulantha S. Mathotaarachchi[2,3], Monica Shin[3,4], Min Su Kang[4,6], Kok Pin Ng[3,7], Joseph Therriault[4], Hanne Struyfs[4,8,9,10,11], Jean-Paul Soucy[2,12,13], Serge Gauthier[1,3], Pedro Rosa-Neto[4,14], *[1]Douglas Hospital Research Centre, Verdun, QC, Canada; [2]McGill University, Montreal, QC, Canada; [3]McGill University Research Centre for Studies in Aging, Verdun, QC, Canada; [4]Translational Neuroimaging Laboratory- McGill University, Verdun, QC, Canada; [5]Centre for Studies on Prevention of Alzheimer's Disease (StoP-AD Centre), Douglas Mental Health Institute, Verdun, QC, Canada; [6]Douglas Mental Health Institute, Montreal, QC, Canada; [7]National Neuroscience Institute, Singapore, Singapore; [8]icometrix, Leuven, Belgium; [9]Reference Center for Biological Markers of Dementia (BIODEM), Antwerp, Belgium; [10]Reference Center for Biological Markers of Dementia (BIODEM), Laboratory of Neurochemistry and Behavior, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium; [11]Institute Born-Bunge, University of Antwerp, Antwerp, Belgium; [12]PERFORM Centre - Concordia University, Montréal, QC, Canada; [13]University of Montreal Hospital Centre, Montreal, QC, Canada; [14]Douglas Mental Health University Institute, Montreal, QC, Canada. Contact e-mail: tharick.alipascoal@mail.mcgill.ca*

**Background:** Brain amyloid-β deposition is the core pathological feature of Alzheimer's disease (AD) and can be detected *in vivo* using positron emission tomography (PET). However, the importance of the regional patterns of amyloid-β abnormality has been highly questioned due to its widespread deposition over the cortex. Here, using a novel analytical framework free of conceptual assumptions, we assess the regional patterns of amyloid-β deposition that are associated with AD dementia. **Methods:** We assessed 211 control, 311 mild cognitive impairment, and 79 AD individuals who underwent [$^{18}$F]florbetapir PET at baseline as well as clinical assessments at baseline and at 2 years. Receiver operating characteristic curves, contrasting controls with AD individuals, assessed the least distance from point to the curve at every brain voxel, which provided the amyloid-β values with the best trade-off between sensitivity and specificity for AD. Finally, we generated a voxel-wise parametric map only with brain regions showing both sensitivity and specificity higher than 0.85. **Results:** Remarkably, the regions with the highest sensitivity and specificity for AD dementia were confined to the brain's default mode network in the precuneus, posterior cingulate, medial prefrontal, and lateral temporal cortices (Fig.1). In contrast, other brain regions with high amyloid-β burden such as the anterior cingulate had low sensitivity and specificity values. **Conclusions:** These results highlight that although amyloid-β deposition occurs widespread over the cortex, the deposition more strongly associated with dementia are confined to the brain's regions default mode network. Interestingly, our results showed




dissociation between the regional levels of amyloid-β burden and the sensitivity and specificity of this burden for a diagnosis of AD. This suggests that the selective regional vulnerability to the toxic effects of Aβ aggregates, at least, plays a role in the progression of AD.

## IC-P-018 NEUROIMAGING-DEFINED AMYLOID AND CEREBROVASCULAR PATHOLOGY ARE ASSOCIATED WITH A NEUROMETABOLIC SIGNATURE OF ALZHEIMER'S DISEASE

**Simon J. Schreiner**[1], Thomas Kirchner[2], Atul Narkhede[3], Michael Wyss[2], Jiri M. G. Van Bergen[1], Stephanie C. Steininger[4], Anton F. Gietl[1], Sandra E. Leh[1,4], Valerie Treyer[5], Alfred Buck[5], Klaas P. Pruessmann[2], Roger M. Nitsch[1], Christoph Hock[1], Anke Henning[2,6], Adam M. Brickman[3], Paul G. Unschuld[1,4], *[1]Institute for Regenerative Medicine, University of Zurich, Schlieren, Switzerland; [2]Institute for Biomedical Engineering, University of Zurich and ETH Zurich, Zurich, Switzerland; [3]Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, NY, USA; [4]Hospital for Psychogeriatric Medicine, University of Zurich, Zurich, Switzerland; [5]University Hospital Zurich, Zurich, Switzerland; [6]Max Planck Institute for Biological Cybernetics, Tubingen, Germany. Contact e-mail: simon.schreiner@gmx.de*

**Background:** To investigate whether white matter hyperintensities (WMH), an MRI-correlate of small-vessel cerebrovascular disease, are associated with a neurometabolic signature of Alzheimer's disease (AD), defined as the metabolic correlates of preclinical ß-amyloid (Aß) pathology and the apolipoprotein-E ε4 allele (APOE-ε4), the major genetic risk factor for sporadic AD. **Methods:** Cognitively normal participants (n=30, age=70±5.6 years, MMSE=29.2±1) received 11C-PiB-PET to quantify Aß, 7 Tesla fluid-attenuated inversion recovery MRI to quantitate WMH, and 7 Tesla high-resolution MR spectroscopic imaging to estimate N-acetylaspartate (NAA), myo-inositol (mI), total-choline (tCho), and creatine (Cr) in posterior cingulate and precuneus (PCP) gray and white matter. We examined relationships of Aß, WMH, and APOE-ε4, and their interactions, with brain metabolites. **Results:** Higher levels of Aß (r= -0.64, p<0.001) and higher WMH volume (r= -0.45, p=0.02) were associated with lower NAA/mI in gray matter. Participants with both high Aß and high WMH had lower NAA/mI compared to those with none or with high level of either Aß or WMH (significant Aß x WMH